RPT1G is the first well-tolerated NAMPT inhibitor, demonstrating safety in healthy volunteers at single and multiple ascending dose levels.Target ...
ImmunoScape Pte. Ltd., an A*STAR spin out backed by Amgen Ventures and EDBi that is developing next-generation TCR-based cancer immunotherapies, today announced an exclusive in-licensing deal with Cue ...
New data show that dual-target CAR T therapy induces durable remissions in children with high-risk B-cell leukaemia, offering ...
Cancer treatment has come a long way, but many of today's therapies still come with steep costs: not just financial, but ...
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to tinostamustine, an investigational therapeutic from Purdue Pharma L.P., for the treatment of patients with malignant ...
Researchers succeeded in creating cells whose proliferation can be controlled. The technique enables new and safe cell therapies. Cell therapies could help in the treatment of hereditary diseases, ...
March Biosciences (March Bio), a clinical stage biotechnology company developing cell therapies for hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted ...
A large Danish study found that an insufficient endometrial biopsy may slightly increase endometrial cancer risk. Learn more about the findings.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback